News & Updates

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

In the first years of use, conjugated estrogens/bazedoxifene (CE/BZA) appears to be associated with slightly higher rates of endometrial cancer and endometrial hyperplasia compared with estrogen/progestin (EP) combination hormone therapy, according to a study.

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

21 Jul 2023

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

In patients with cutaneous squamous cell carcinoma (cSCC) presenting with satellitosis or in-transit metastasis (S-ITM), the size and the number of S-ITM lesions are associated with a higher risk of relapse, while the number of S-ITM confers an increased risk of specific death, reveals a study.

S-ITM lesions predict relapse in cutaneous SCC

19 Jul 2023

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023 by

In the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (LR-MDS), luspatercept seems to perform better than epoetin alfa at restoring iron stores, according to the interim results of the open-label phase III COMMANDS trial.

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

17 Jul 2023

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Treatment of Merkel cell carcinoma (MCC), a rare neuroendocrine skin cancer with high mortality and rising incidence, at either an academic or a high-volume centre tends to lead to better patient survival, as shown in a recent study.

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

17 Jul 2023

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023 by

Neutrophils play a crucial role in suppressing or promoting tumour growth. Gene-edited neutrophils with SMAD3 deletion enhance neutrophil-mediated antitumour activity in non-small-cell lung cancer (NSCLC), according to researchers from the Chinese University of Hong Kong (CUHK).

Neutrophils may pave the way for new-generation immunotherapy

17 Jul 2023

$CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma$

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

15 Jul 2023 by

Diffuse large B-cell lymphoma (DLBCL) is the most frequently occurring subtype of non-Hodgkin lymphoma. Although curability is high following first-line immunochemotherapy, around 40 percent of patients will relapse or exhibit refractory disease, which dramatically reduces life expectancy. [Best Pract Res Clin Haematol 2018;31:209-216] Despite salvage chemo-immunotherapy and stem cell transplantation, patients with relapsed/refractory (R/R) DLBCL have a dismal prognosis. In the SCHOLAR-1 study, the median overall survival (OS) for refractory DLBCL was 6.3 months, the complete response rate was 7 percent, and the 1-year OS rate was 28 percent. [Blood 2017;130:1800-1808]

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

15 Jul 2023

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023 by

The FLT3 type II inhibitor quizartinib, when combined with induction and consolidated therapy and continued for up to 12 cycles, yields survival benefits such as prolonged overall and relapse-free survival in patients with newly diagnosed wild-type acute myeloid leukaemia (AML), as shown in the interim results of the phase II study QUIWI.

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

13 Jul 2023

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023 by

Treatment with mirvetuximab soravtansine, an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα), led to significantly better survival outcomes in women with platinum-resistant ovarian cancer (PROC) compared with the investigator’s choice of chemotherapy, according to the MIRASOL trial presented at ASCO 2023.

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

13 Jul 2023

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

12 Jul 2023

A prediction model on disease recurrence for low-risk, resected stage I lung adenocarcinoma can classify postoperative patients with available clinical information and may even aid in personalizing a follow-up strategy and future adjuvant therapy, reports a study.

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

12 Jul 2023

S-ketamine anaesthesia improves recovery following modified radical mastectomy

12 Jul 2023 by

A prospective randomized controlled trial of breast cancer (BC) patients undergoing modified radical mastectomy (MRM) finds that S-ketamine used in place of sufentanil for general anaesthesia (GA) improves postoperative recovery.

S-ketamine anaesthesia improves recovery following modified radical mastectomy

12 Jul 2023

News & Updates

Filter by Specialty:

Specialty:

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

Conjugated estrogens/bazedoxifene use tied to higher rates of endometrial cancer, hyperplasia

S-ITM lesions predict relapse in cutaneous SCC

S-ITM lesions predict relapse in cutaneous SCC

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Luspatercept bests epoetin alfa in head-to-head LR–MDS-related anaemia trial

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Does the type of facility affect outcomes in patients with Merkel cell carcinoma?

Neutrophils may pave the way for new-generation immunotherapy

Neutrophils may pave the way for new-generation immunotherapy

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

QUIWI: FLT3 type II inhibitor confers survival advantage in acute myeloid leukaemia

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Mirvetuximab soravtansine improves survival in platinum-resistant ovarian cancer

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

Prediction model for stage I NSCLC refines follow-up strategy, personalizes therapy

S-ketamine anaesthesia improves recovery following modified radical mastectomy

S-ketamine anaesthesia improves recovery following modified radical mastectomy